Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Sulfonamide Antibacterial [EPC]
Silver Sulfadiazine is a topical sulfonamide antibacterial agent used primarily to prevent and treat infections in second- and third-degree burns. It works by releasing silver ions and inhibiting bacterial folic acid synthesis.
Name
Silver Sulfadiazine
Raw Name
SILVER SULFADIAZINE
Category
Sulfonamide Antibacterial [EPC]
Drug Count
4
Variant Count
24
Last Verified
February 17, 2026
RxCUI
106351, 208186, 208185
UNII
W46JY43EJR
About Silver Sulfadiazine
Silver Sulfadiazine is a topical sulfonamide antibacterial agent used primarily to prevent and treat infections in second- and third-degree burns. It works by releasing silver ions and inhibiting bacterial folic acid synthesis.
Detailed information about Silver Sulfadiazine
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Silver Sulfadiazine.
Silver Sulfadiazine (SSD) is a potent topical antimicrobial agent primarily utilized in the medical field for the prevention and treatment of wound sepsis in patients with second-degree (partial-thickness) and third-degree (full-thickness) burns. Belonging to the drug class known as sulfonamide antibacterials (EPC), Silver Sulfadiazine is a broad-spectrum antibiotic that combines the antimicrobial properties of both silver ions and sulfadiazine. It is most commonly formulated as a 1% white, water-miscible cream. According to the FDA-approved labeling, this medication was first approved in the United States in 1973 and has since remained a cornerstone of burn management protocols worldwide.
Silver Sulfadiazine is unique because it is not merely a combination of two agents; it is a chemical complex where the silver is bound to the sulfadiazine molecule. When applied to a burn wound, the compound reacts with the serum and tissue fluids, slowly and steadily releasing silver ions into the wound bed. This sustained release is critical for maintaining an environment that is hostile to bacterial colonization without causing the rapid, overwhelming toxicity that can sometimes be associated with other silver-based compounds. Healthcare providers typically choose Silver Sulfadiazine because of its ease of application, its ability to remain active in the presence of wound exudate, and its efficacy against a wide range of pathogens, including the notoriously difficult-to-treat Pseudomonas aeruginosa.
The mechanism of action of Silver Sulfadiazine is multifaceted, exerting its bactericidal (bacteria-killing) effects through two distinct pathways. At the molecular level, the silver ions released from the cream bind to the bacterial cell membranes and cell walls. This binding disrupts the structural integrity of the cell, leading to leakage of cellular contents and eventual cell death. Furthermore, silver ions are known to bind to bacterial DNA, interfering with the replication and transcription processes, which effectively halts the reproduction of the microorganisms.
Simultaneously, the sulfadiazine component of the molecule acts as a competitive inhibitor of the enzyme dihydropteroate synthase. This enzyme is essential for the synthesis of bacterial folic acid. Because bacteria must synthesize their own folic acid to produce DNA and RNA, the inhibition of this pathway leads to a bacteriostatic effect (inhibiting growth). The synergy between the direct membrane disruption by silver and the metabolic inhibition by sulfadiazine makes Silver Sulfadiazine effective against both Gram-positive and Gram-negative bacteria, as well as certain yeasts like Candida albicans. It is important to note that while it is highly effective against microbes, it is designed to be minimally toxic to human tissue cells, though it can occasionally delay the rate of skin graft 'take' or epithelialization (the process of skin regrowth).
Silver Sulfadiazine is intended for topical application, and systemic absorption varies significantly depending on the surface area of the burn and the integrity of the skin. In patients with extensive burns, sulfadiazine can be absorbed into the systemic circulation in significant amounts. Studies have shown that serum concentrations of sulfadiazine can reach levels of 8 mg/dL to 12 mg/dL in patients with large-area burns. Silver absorption is generally much lower, though it can accumulate in tissues over long-term use. Absorption is not significantly affected by food, as the drug is not administered orally.
Once absorbed systemically, sulfadiazine is distributed throughout the body's tissues. It has the capacity to cross the blood-brain barrier and the placental barrier. Protein binding for sulfadiazine in the blood is approximately 38% to 48%. Silver ions that enter the circulation are typically bound to albumin or other plasma proteins and can be deposited in various organs, including the liver, kidneys, and skin.
Sulfadiazine is primarily metabolized in the liver via acetylation. This process creates acetylsulfadiazine, which lacks antimicrobial activity but remains systemically present until excreted. The rate of metabolism can vary based on an individual's genetic 'acetylator status,' though this is more clinically relevant for oral sulfonamides than for topical SSD.
The elimination of absorbed sulfadiazine is primarily renal (through the kidneys). The half-life of sulfadiazine in the blood is approximately 10 hours in patients with normal renal function. Silver is primarily eliminated through the biliary tract (feces), with only trace amounts appearing in the urine.
The primary FDA-approved indication for Silver Sulfadiazine is the prevention and treatment of wound sepsis in patients with second- and third-degree burns. By keeping the bacterial count in the burn eschar (the dead tissue that forms over a burn) low, it prevents the bacteria from invading the underlying healthy tissue, which could otherwise lead to systemic sepsis (a life-threatening blood infection).
Off-label uses, which your healthcare provider may consider, include the treatment of other types of skin wounds, such as pressure ulcers (bedsores) or chronic venous stasis ulcers, particularly when these wounds show signs of infection or are at high risk for bacterial colonization. However, the evidence for SSD in non-burn wounds is less robust than its primary indication.
Silver Sulfadiazine is almost exclusively available as a 1% topical cream. It is typically packaged in:
There are no oral, injectable, or ophthalmic (eye) forms of Silver Sulfadiazine. It must never be applied to the eyes or taken internally.
> Important: Only your healthcare provider can determine if Silver Sulfadiazine is right for your specific condition. The severity of a burn requires professional medical assessment to ensure proper wound care and to prevent complications like infection or permanent scarring.
For the treatment of burn wounds in adults, Silver Sulfadiazine 1% cream should be applied under aseptic (sterile) conditions. The standard procedure involves applying a layer of cream approximately 1/16th of an inch (1.5 mm) thick over the affected area. The wound should be covered with the cream at all times. If the cream is removed by patient activity or through wound drainage (exudate), it must be reapplied immediately to maintain the antimicrobial barrier.
Applications are typically performed once to twice daily. In cases of severe infection or high amounts of drainage, your healthcare provider may recommend more frequent applications. The treatment should continue until satisfactory healing has occurred or until the burn site is ready for skin grafting. It is not intended for long-term use beyond the healing of the specific burn injury.
Silver Sulfadiazine is approved for use in children; however, its use is strictly contraindicated in premature infants and neonates (newborns) under the age of 2 months. This is because sulfonamides can displace bilirubin from albumin binding sites, potentially leading to kernicterus (a serious form of brain damage caused by high bilirubin levels). For children over 2 months of age, the dosage and application method are the same as for adults: a 1/16th inch layer applied once or twice daily to the burned area. Parents should ensure the child does not ingest the cream or rub it into their eyes.
Because a significant portion of absorbed sulfadiazine is excreted by the kidneys, patients with impaired renal function may require closer monitoring. While the dose of the cream itself is not typically adjusted, healthcare providers may monitor serum sulfonamide levels and kidney function tests (creatinine) to ensure that systemic accumulation does not reach toxic levels, especially in patients with large-area burns.
Patients with liver disease should be monitored closely. Since the liver is responsible for the acetylation of sulfadiazine, impaired hepatic function could lead to higher levels of the active drug in the bloodstream. If signs of systemic toxicity occur, the frequency of application may need to be reduced.
Clinical studies have not identified specific differences in response between elderly and younger patients. However, because elderly patients are more likely to have decreased renal or hepatic function, healthcare providers often exercise caution and monitor these patients more frequently during treatment.
Silver Sulfadiazine is for topical use only. Follow these steps for application:
If you miss an application or if the cream is rubbed off, apply it as soon as you remember. The burn wound should be covered with the medication at all times to ensure continuous protection against infection. Do not apply a double layer to make up for a missed application; simply restore the 1/16th inch thickness.
Systemic overdose from topical application is rare but can occur if the cream is applied to very large surface areas over a long period. Symptoms of systemic sulfonamide toxicity include nausea, vomiting, dizziness, and skin rashes. If someone accidentally swallows the cream, contact a poison control center or seek emergency medical help immediately. In the event of suspected systemic toxicity, your doctor may recommend increasing fluid intake to help the kidneys flush out the sulfadiazine.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop using the medication without medical guidance, as this could increase the risk of a serious wound infection.
The most frequently reported side effect of Silver Sulfadiazine is a transient decrease in white blood cell count, known as leukopenia. This typically occurs within 2 to 4 days of starting treatment. In most patients, the white blood cell count returns to normal even while treatment continues, usually within a few days. Patients may also experience a localized burning or stinging sensation immediately after the cream is applied. This sensation is usually brief and tends to diminish as the wound begins to heal.
> Warning: Stop taking Silver Sulfadiazine and call your doctor immediately if you experience any of these serious reactions. While rare with topical use, systemic absorption can lead to life-threatening conditions.
With prolonged use (weeks to months), there is an increased risk of systemic accumulation of both silver and sulfadiazine. Long-term use can lead to delayed wound healing in some patients, as the silver may be slightly toxic to the keratinocytes (skin cells) needed for re-epithelialization. Chronic use over large areas also increases the risk of the aforementioned argyria and potential kidney or liver strain.
No FDA black box warnings for Silver Sulfadiazine. However, the FDA does emphasize the contraindication in neonates and the risk of serious sulfonamide-related skin reactions.
Report any unusual symptoms or changes in your skin's appearance to your healthcare provider immediately. Regular blood tests may be required if the medication is used over a large portion of the body.
Silver Sulfadiazine is a potent antimicrobial intended only for use on the skin. It should never be used in or near the eyes, as it can cause severe irritation. Patients must be aware that while the cream is highly effective at preventing infection, it does not replace the need for professional surgical debridement or fluid resuscitation in severe burn cases. It is also essential to use aseptic techniques (sterile gloves and tools) during application to avoid contaminating the medication or the wound.
No FDA black box warnings for Silver Sulfadiazine.
Patients with a known allergy to sulfonamide drugs (often called 'sulfa drugs') should not use Silver Sulfadiazine. Cross-sensitivity can occur, leading to severe allergic reactions, including rashes, hives, or life-threatening anaphylaxis. If you have ever had a reaction to an oral antibiotic like Bactrim or Septra, inform your doctor before using this cream.
Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at an increased risk of hemolytic anemia (the destruction of red blood cells) when using sulfonamides. If you have this genetic condition, your doctor will need to weigh the risks and benefits carefully and monitor your blood counts closely.
Silver Sulfadiazine can make the treated skin more sensitive to sunlight. Exposure to UV light can cause the silver in the cream to darken, leading to temporary or permanent skin staining. Patients should keep treated areas covered or avoid direct sunlight.
If Silver Sulfadiazine is applied to a large surface area (typically more than 20% of the body), your healthcare provider will likely perform regular monitoring, including:
Silver Sulfadiazine is not known to affect the ability to drive or operate machinery. However, the pain associated with a severe burn or the use of pain medications prescribed alongside SSD may impair these abilities.
There are no direct interactions between topical Silver Sulfadiazine and alcohol. However, alcohol can dehydrate the body, which is counterproductive during burn recovery. Consult your doctor regarding alcohol consumption during your recovery period.
There is no withdrawal syndrome associated with stopping Silver Sulfadiazine. However, stopping the medication before the wound has adequately healed or before a skin graft has 'taken' can significantly increase the risk of a life-threatening bacterial infection. Always consult your doctor before discontinuing treatment.
> Important: Discuss all your medical conditions, especially kidney disease, liver disease, or blood disorders, with your healthcare provider before starting Silver Sulfadiazine.
Proteolytic Enzymes (e.g., Collagenase): Silver Sulfadiazine should not be used in combination with topical proteolytic enzymes like collagenase (Santyl). Silver ions can inactivate these enzymes, rendering the debriding agent ineffective. If both are required, they must be used at different times or on different areas of the wound as directed by a specialist.
Cimetidine: There have been reports that the concurrent use of cimetidine (a common heartburn medication) and Silver Sulfadiazine may increase the incidence and severity of leukopenia (low white blood cell count). Patients taking cimetidine should have their blood counts monitored more frequently.
Systemic Sulfonamides: If a patient is taking oral sulfonamides while using topical SSD, the risk of systemic sulfonamide toxicity (including SJS/TEN and crystalluria) is significantly increased due to the cumulative dose.
Oral Hypoglycemics (e.g., Glyburide, Glipizide): Systemically absorbed sulfadiazine can potentiate the effects of certain oral diabetes medications, potentially leading to hypoglycemia (low blood sugar). While the amount absorbed from the skin is usually small, monitoring blood glucose is advised for diabetic patients with large burns.
Phenytoin: Sulfonamides can inhibit the metabolism of phenytoin (an anti-seizure medication), leading to increased phenytoin levels and potential toxicity. Monitor for signs of phenytoin overdose, such as nystagmus (involuntary eye movement) or ataxia (loss of coordination).
Warfarin: Sulfadiazine may displace warfarin from protein-binding sites or interfere with its metabolism, potentially increasing the risk of bleeding. Patients on anticoagulants should have their INR monitored closely if SSD is used over large areas.
There are no known significant food interactions with topical Silver Sulfadiazine. However, maintaining adequate hydration (water intake) is essential to prevent the formation of sulfonamide crystals in the kidneys if the drug is absorbed systemically.
There is limited data on interactions between SSD and herbal supplements. However, patients should avoid applying other topical herbal 'burn salves' or creams to the same area as Silver Sulfadiazine, as these may interfere with the silver ion release or alter the pH of the wound bed, reducing the drug's efficacy.
Silver Sulfadiazine may interfere with certain laboratory tests:
For each major interaction, the mechanism usually involves either direct chemical inactivation (as with enzymes) or metabolic interference in the liver (CYP450 pathways) and kidney. The clinical consequence is typically an increased risk of side effects or a reduction in the efficacy of one of the medications. Management usually involves spacing out applications or choosing alternative medications.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, even those applied to the skin.
Silver Sulfadiazine must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare professional include:
Patients who are allergic to certain diuretics (like furosemide or thiazides) or certain diabetes medications (sulfonylureas) may occasionally show cross-sensitivity to sulfonamides like Silver Sulfadiazine. Always inform your doctor of any drug allergies, even if they seem unrelated to topical treatments.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to antibiotics, before prescribing Silver Sulfadiazine.
Silver Sulfadiazine is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. However, its use is strictly contraindicated at term (near the time of delivery) because of the risk that absorbed sulfonamides could cause kernicterus in the infant. During earlier stages of pregnancy, SSD should only be used if the potential benefit to the mother outweighs the potential risk to the fetus. There is no evidence suggesting SSD is useful in fertility treatments.
It is not known whether Silver Sulfadiazine is excreted in human breast milk. However, it is known that other sulfonamides are excreted in milk and can increase the risk of kernicterus in nursing infants, particularly those who are ill, stressed, or premature. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
As previously noted, Silver Sulfadiazine is contraindicated in infants under 2 months of age. For children older than 2 months, it is considered safe and effective for burn care. There are no known long-term effects on growth or development when used as directed for short-term burn management. It is not approved for the treatment of common childhood skin conditions like diaper rash or eczema.
Elderly patients may be at a higher risk for systemic side effects if they have age-related declines in kidney or liver function. While there is no specific evidence that SSD increases fall risk, the systemic absorption of sulfonamides can occasionally cause dizziness in sensitive individuals. Polypharmacy is a major concern in the elderly; therefore, the potential for SSD to interact with oral medications like warfarin or glyburide must be carefully managed.
In patients with a reduced Glomerular Filtration Rate (GFR), the excretion of absorbed sulfadiazine is slowed. While the topical dose is not typically adjusted, the frequency of application may be reduced if serum sulfonamide levels rise. SSD is not significantly cleared by hemodialysis, so patients on dialysis require even more vigilant monitoring for signs of toxicity.
There are no specific dosing adjustments provided for patients with hepatic impairment based on Child-Pugh classification. However, because the liver is the primary site for sulfadiazine metabolism, patients with liver failure are at a higher risk for systemic toxicity and should be monitored for signs of sulfonamide-induced liver injury.
> Important: Special populations require individualized medical assessment to ensure that the benefits of infection prevention outweigh the risks of systemic absorption.
Silver Sulfadiazine is a topical antimicrobial agent that acts on the bacterial cell wall and cell membrane. Upon contact with wound exudate, the silver sulfadiazine complex dissociates. The silver ions ($Ag^+$) are released and bind to the bacterial cell surface, causing immediate structural damage. Silver also penetrates the cell and binds to bacterial DNA, preventing the double helix from unzipping and thus halting DNA replication. Simultaneously, the sulfadiazine moiety acts as a competitive antagonist of para-aminobenzoic acid (PABA), inhibiting the enzyme dihydropteroate synthase. This prevents the synthesis of dihydrofolic acid, a precursor to the folic acid required for bacterial purine and pyrimidine synthesis. This dual-action approach—physical destruction by silver and metabolic blockade by sulfadiazine—provides a broad spectrum of bactericidal activity.
The antimicrobial effect of Silver Sulfadiazine is concentration-dependent at the wound surface. It provides a sustained release of silver, maintaining inhibitory concentrations for up to 24 hours. There is no evidence of significant resistance development when used for short-term burn care, although some strains of Pseudomonas have shown reduced susceptibility in long-term hospital settings. The duration of effect is tied to the presence of the cream; once the cream is washed away or absorbed by dressings, the antimicrobial barrier is lost.
| Parameter | Value |
|---|---|
| Bioavailability | Variable (Topical: 1-10% sulfadiazine absorbed) |
| Protein Binding | 38% - 48% (Sulfadiazine) |
| Half-life | ~10 hours (Sulfadiazine) |
| Tmax | 3-11 days (Peak systemic levels in large burns) |
| Metabolism | Hepatic (Acetylation) |
| Excretion | Renal (Sulfadiazine), Biliary/Fecal (Silver) |
Silver Sulfadiazine is classified as a Sulfonamide Antibacterial. It is distinct from other sulfonamides because of the silver ion integration. Related medications include silver nitrate (an older, more irritating burn treatment) and mafenide acetate (another topical sulfonamide used for burns that can cause metabolic acidosis).
Medications containing this ingredient
Common questions about Silver Sulfadiazine
Silver Sulfadiazine is primarily used to prevent and treat infections in patients with second- and third-degree burns. It acts as a topical antimicrobial barrier that keeps bacterial counts low in the burn eschar, which is the dead tissue that forms over a wound. By preventing bacterial growth, it significantly reduces the risk of the infection spreading into the bloodstream, a condition known as sepsis. It is effective against a wide range of bacteria, including Pseudomonas and yeast. Your doctor may also occasionally use it off-label for other types of skin ulcers or infected wounds.
The most common side effect is a temporary drop in the white blood cell count, called leukopenia, which usually happens within the first few days of treatment and often resolves on its own. Many patients also report a mild stinging or burning sensation immediately after the cream is applied to the wound. In some cases, the skin may develop a brownish or grayish discoloration, especially if the treated area is exposed to sunlight. Other common issues include localized skin rashes or itching as the wound heals. Always report any new or worsening skin irritation to your healthcare provider.
There is no known direct interaction between topical Silver Sulfadiazine cream and alcohol consumption. However, alcohol can lead to dehydration and may interfere with the body's natural healing processes, which is not ideal when recovering from a significant burn injury. If you are also taking oral pain medications or other antibiotics for your burn, those may have very dangerous interactions with alcohol. It is always best to consult with your doctor about whether alcohol is safe for you during your specific recovery period. Staying well-hydrated with water is much more beneficial for wound healing.
Silver Sulfadiazine is generally avoided during pregnancy unless the benefits clearly outweigh the risks, and it is strictly forbidden at term (near delivery). The concern is that the absorbed sulfonamide can cross the placenta and interfere with the baby's bilirubin processing, potentially leading to a serious brain condition called kernicterus. If you are pregnant or planning to become pregnant, you must inform your doctor before using this medication. They will determine the safest course of action for treating your burn while protecting the health of your developing baby. It is classified as FDA Category B for earlier stages of pregnancy.
Silver Sulfadiazine begins working to kill bacteria almost immediately upon contact with the wound bed as the silver ions are released. However, you will not see 'visible' results in terms of wound healing for several days, as the primary goal of the medication is to prevent infection rather than speed up skin growth. The cream provides a continuous antimicrobial barrier as long as it is present on the skin. Treatment typically continues until the wound is healed enough for a skin graft or until the skin has successfully regrown. Your doctor will monitor the wound daily to assess progress.
You should not stop using Silver Sulfadiazine until your healthcare provider tells you the wound is sufficiently healed. Stopping the treatment prematurely can leave the burn wound vulnerable to bacterial colonization and serious infection, which can delay healing and increase scarring. There is no risk of 'withdrawal' symptoms like you might see with some internal medications, but the risk of infection is a major concern. If you are experiencing side effects that make you want to stop, contact your doctor immediately to discuss alternative treatments. Consistent application is key to a successful recovery.
If you miss an application or if the cream has been rubbed off by clothing or bedding, you should apply a new layer as soon as you realize it. The goal is to keep the burn wound covered with a 1/16th inch layer of the cream at all times to maintain the protective barrier. You do not need to apply extra cream to 'make up' for the missed time; just restore the standard thickness. If it is almost time for your next scheduled application, simply apply the regular amount and stay on your normal schedule. Keeping the wound covered is the most important factor.
No, Silver Sulfadiazine does not cause weight gain. It is a topical antibiotic that works locally on the skin and does not affect the body's metabolism or appetite in a way that would lead to weight changes. If you notice sudden weight gain or swelling (edema) while being treated for a burn, it is more likely related to the body's inflammatory response to the injury or the large amounts of intravenous fluids often given to burn patients. You should report any significant swelling or rapid weight changes to your medical team immediately, as it could indicate a fluid balance issue.
Silver Sulfadiazine can interact with certain other medications, especially if it is applied to a large area where more of it is absorbed into the bloodstream. It should not be used at the same time as topical proteolytic enzymes like collagenase, because the silver will inactivate the enzymes. It may also interact with oral medications like cimetidine, blood thinners like warfarin, or diabetes drugs. Always provide your doctor with a complete list of all medications you are taking, including over-the-counter supplements. They will monitor you for potential interactions and adjust your treatment plan if necessary.
Yes, Silver Sulfadiazine is widely available as a generic 1% topical cream. Generic versions are required by the FDA to have the same active ingredient, strength, and efficacy as the brand-name versions, such as Silvadene or SSD Cream. Using the generic version is a cost-effective way to receive the same high-quality burn care. Most hospitals and pharmacies stock the generic version as their standard treatment for burn wounds. Your insurance plan is also more likely to cover the generic form of this medication.